These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
65 related items for PubMed ID: 9863887
21. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M, Jung D, Spector SA, Bryson Y. Clin Infect Dis; 1999 May; 28(5):1109-18. PubMed ID: 10452644 [Abstract] [Full Text] [Related]
22. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiró A, Aranda M, Barrufet P, Martínez-Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J. Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928 [Abstract] [Full Text] [Related]
23. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression. Ford J, Cornforth D, Hoggard PG, Cuthbertson Z, Meaden ER, Williams I, Johnson M, Daniels E, Hsyu P, Back DJ, Khoo SH. Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539 [Abstract] [Full Text] [Related]
24. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? Colombo S, Telenti A, Buclin T, Furrer H, Lee BL, Biollaz J, Decosterd LA, Swiss HIV Cohort Study. Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716 [Abstract] [Full Text] [Related]
28. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection. Wilkins E. J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268 [No Abstract] [Full Text] [Related]
31. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M. Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192 [Abstract] [Full Text] [Related]
32. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Benator DA, Weiner MH, Burman WJ, Vernon AA, Zhao ZA, Khan AE, Jones BE, Sandman L, Engle M, Silva-Trigo C, Hsyu PH, Becker MI, Peloquin CA, Tuberculosis Trials Consortium. Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762 [Abstract] [Full Text] [Related]
33. Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. Almond LM, Edirisinghe D, Dalton M, Bonington A, Back DJ, Khoo SH. Clin Pharmacol Ther; 2005 Aug; 78(2):132-42. PubMed ID: 16084848 [Abstract] [Full Text] [Related]
39. Pharmacokinetics of nelfinavir during haemodialysis in a patient with HIV infection. Armbruster C, Vorbach H, El Menyawi I, Meisl FT, Neumann I. AIDS; 2000 Jan 07; 14(1):99-101. PubMed ID: 10714579 [No Abstract] [Full Text] [Related]